Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Investigational New Drugs|December 1, 2017
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skippingS Betty Yan, Suzane L Um, Victoria L Peek, et al.
Plos One|November 22, 2013
Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotideBlake A Jacobson, Saritha C Thumma, Joseph Jay-Dixon, et al.
Journal of Drugs in Dermatology : JDD|August 2, 2024
Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body AreasAlice B Gottlieb, April Armstrong, Andrew Blauvelt, et al.
Cell Reports|December 4, 2014
Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypesChristos G Gkogkas, Arkady Khoutorsky, Ruifeng Cao, et al.
Cancer Research|January 15, 2011
Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastasesBruce W Konicek, Jennifer R Stephens, Ann M McNulty, et al.
Cancer Research|August 17, 2005
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenograftsJeremy R Graff, Ann M McNulty, Kimberly Ross Hanna, et al.
Cancer Research|April 23, 2009
eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survivalJeremy R Graff, Bruce W Konicek, Rebecca L Lynch, et al.
Oncotarget|March 24, 2018
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumorsBruce W Konicek, Andrew R Capen, Kelly M Credille, et al.
Investigational New Drugs|January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsS Betty Yan, Victoria L Peek, Rose Ajamie, et al.
The Journal of Clinical Investigation|September 6, 2007
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicityJeremy R Graff, Bruce W Konicek, Thomas M Vincent, et al.
Pageof 2